RNA, U6atac small nuclear 3, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6ATAC3P profile across patient tissues and cancer cell-line models. RNU6ATAC3P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC3P is differentially expressed in 5, with the highest sampling consensus in CHOL. Additionally, RNU6ATAC3P RNA expression shows 11,455 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, CHOL, and THYM as cancer lineages where RNU6ATAC3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC3P survival associations across molecular data types. RNU6ATAC3P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC3P RNA expression–survival associations across cancer types. High RNU6ATAC3P expression shows unfavorable associations in KIRC, KICH, ESCA, OV, ACC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU6ATAC3P RNA expression.
This table summarizes RNU6ATAC3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC3P shows lower tumor expression in KIRC and higher tumor expression in CHOL, LUSC, BLCA and BRCA. The CHOL box plot shows higher RNU6ATAC3P RNA expression in tumor versus normal tissue (log2 FC = +1.100, t-test p < 0.001).
This table shows molecular features associated with RNU6ATAC3P in patient tissues and cancer cell lines. In patient samples, RNU6ATAC3P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
